Cash Flow Statement

Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Change in Taxes Change in Taxes Change in Working Capital Change in Working Capital Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt repayments

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Leases Long-Term Debt Issuances Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Preferred Shares Issued Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding Short-Term Debt repayments

Ratios

Gain Therapeutics (GANX) Short-Term Debt repayments (2022 - 2025)

Gain Therapeutics has reported Short-Term Debt repayments over the past 4 years, most recently at $25025.0 for Q4 2025.

Quarterly results put Short-Term Debt repayments at $25025.0 for Q4 2025, up 9.86% from a year ago — trailing twelve months through Dec 2025 was $96501.0 (up 6.19% YoY), and the annual figure for FY2025 was $96501.0, up 6.19%.
Short-Term Debt repayments for Q4 2025 was $25025.0 at Gain Therapeutics, roughly flat from $24996.0 in the prior quarter.
Over the last five years, Short-Term Debt repayments for GANX hit a ceiling of $37974.0 in Q1 2022 and a floor of -$1363.0 in Q2 2022.
Median Short-Term Debt repayments over the past 4 years was $22604.5 (2023), compared with a mean of $22201.3.
Peak annual rise in Short-Term Debt repayments hit 1732.13% in 2023, while the deepest fall reached 43.09% in 2023.
Gain Therapeutics' Short-Term Debt repayments stood at $21582.0 in 2022, then increased by 4.62% to $22579.0 in 2023, then rose by 0.89% to $22780.0 in 2024, then rose by 9.86% to $25025.0 in 2025.
The last three reported values for Short-Term Debt repayments were $25025.0 (Q4 2025), $24996.0 (Q3 2025), and $24238.0 (Q2 2025) per Business Quant data.